img

Global Pneumonia Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pneumonia Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines.
The global Pneumonia Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pneumonia Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Pneumonia Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Pneumonia Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Pneumonia Vaccine include Pfizer Inc., Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Johnson & Johnson, Astellas Pharma Inc., Astrazeneca Plc. and CSL Limited, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pneumonia Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pneumonia Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Pneumonia Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pneumonia Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Pfizer Inc.
Glaxosmithkline Plc.
Merck & Co., Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Johnson & Johnson
Astellas Pharma Inc.
Astrazeneca Plc.
CSL Limited
Emergent Biosolutions
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
By Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
By Application
Pneumonia
Meningitis
Sepsis
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pneumonia Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumonia Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pneumonia Vaccine Definition
1.2 Market by Type
1.2.1 Global Pneumonia Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Pneumococcal Conjugate Vaccine (PCV13)
1.2.3 Pneumococcal Polysaccharide Vaccine (PPSV23)
1.2.4 Other
1.3 Market Segment by Application
1.3.1 Global Pneumonia Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Pneumonia
1.3.3 Meningitis
1.3.4 Sepsis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pneumonia Vaccine Sales
2.1 Global Pneumonia Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Pneumonia Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pneumonia Vaccine Revenue by Region
2.3.1 Global Pneumonia Vaccine Revenue by Region (2018-2024)
2.3.2 Global Pneumonia Vaccine Revenue by Region (2024-2034)
2.4 Global Pneumonia Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pneumonia Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pneumonia Vaccine Sales Quantity by Region
2.6.1 Global Pneumonia Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Pneumonia Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pneumonia Vaccine Sales Quantity by Manufacturers
3.1.1 Global Pneumonia Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pneumonia Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pneumonia Vaccine Sales in 2022
3.2 Global Pneumonia Vaccine Revenue by Manufacturers
3.2.1 Global Pneumonia Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Pneumonia Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pneumonia Vaccine Revenue in 2022
3.3 Global Pneumonia Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Pneumonia Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pneumonia Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Pneumonia Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pneumonia Vaccine Sales Quantity by Type
4.1.1 Global Pneumonia Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pneumonia Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pneumonia Vaccine Revenue by Type
4.2.1 Global Pneumonia Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Pneumonia Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Pneumonia Vaccine Price by Type
4.3.1 Global Pneumonia Vaccine Price by Type (2018-2024)
4.3.2 Global Pneumonia Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pneumonia Vaccine Sales Quantity by Application
5.1.1 Global Pneumonia Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pneumonia Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pneumonia Vaccine Revenue by Application
5.2.1 Global Pneumonia Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Pneumonia Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Pneumonia Vaccine Price by Application
5.3.1 Global Pneumonia Vaccine Price by Application (2018-2024)
5.3.2 Global Pneumonia Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pneumonia Vaccine Sales by Company
6.1.1 North America Pneumonia Vaccine Revenue by Company (2018-2024)
6.1.2 North America Pneumonia Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Pneumonia Vaccine Market Size by Type
6.2.1 North America Pneumonia Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Pneumonia Vaccine Revenue by Type (2018-2034)
6.3 North America Pneumonia Vaccine Market Size by Application
6.3.1 North America Pneumonia Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Pneumonia Vaccine Revenue by Application (2018-2034)
6.4 North America Pneumonia Vaccine Market Size by Country
6.4.1 North America Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pneumonia Vaccine Revenue by Country (2018-2034)
6.4.3 North America Pneumonia Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pneumonia Vaccine Sales by Company
7.1.1 Europe Pneumonia Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Pneumonia Vaccine Revenue by Company (2018-2024)
7.2 Europe Pneumonia Vaccine Market Size by Type
7.2.1 Europe Pneumonia Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Pneumonia Vaccine Revenue by Type (2018-2034)
7.3 Europe Pneumonia Vaccine Market Size by Application
7.3.1 Europe Pneumonia Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Pneumonia Vaccine Revenue by Application (2018-2034)
7.4 Europe Pneumonia Vaccine Market Size by Country
7.4.1 Europe Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pneumonia Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Pneumonia Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pneumonia Vaccine Sales by Company
8.1.1 China Pneumonia Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Pneumonia Vaccine Revenue by Company (2018-2024)
8.2 China Pneumonia Vaccine Market Size by Type
8.2.1 China Pneumonia Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Pneumonia Vaccine Revenue by Type (2018-2034)
8.3 China Pneumonia Vaccine Market Size by Application
8.3.1 China Pneumonia Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Pneumonia Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pneumonia Vaccine Sales by Company
9.1.1 APAC Pneumonia Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Pneumonia Vaccine Revenue by Company (2018-2024)
9.2 APAC Pneumonia Vaccine Market Size by Type
9.2.1 APAC Pneumonia Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Pneumonia Vaccine Revenue by Type (2018-2034)
9.3 APAC Pneumonia Vaccine Market Size by Application
9.3.1 APAC Pneumonia Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Pneumonia Vaccine Revenue by Application (2018-2034)
9.4 APAC Pneumonia Vaccine Market Size by Region
9.4.1 APAC Pneumonia Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pneumonia Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Pneumonia Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pneumonia Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pneumonia Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pneumonia Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pneumonia Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Information
11.1.2 Pfizer Inc. Overview
11.1.3 Pfizer Inc. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Pfizer Inc. Pneumonia Vaccine Products and Services
11.1.5 Pfizer Inc. Pneumonia Vaccine SWOT Analysis
11.1.6 Pfizer Inc. Recent Developments
11.2 Glaxosmithkline Plc.
11.2.1 Glaxosmithkline Plc. Company Information
11.2.2 Glaxosmithkline Plc. Overview
11.2.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Glaxosmithkline Plc. Pneumonia Vaccine Products and Services
11.2.5 Glaxosmithkline Plc. Pneumonia Vaccine SWOT Analysis
11.2.6 Glaxosmithkline Plc. Recent Developments
11.3 Merck & Co., Inc.
11.3.1 Merck & Co., Inc. Company Information
11.3.2 Merck & Co., Inc. Overview
11.3.3 Merck & Co., Inc. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Merck & Co., Inc. Pneumonia Vaccine Products and Services
11.3.5 Merck & Co., Inc. Pneumonia Vaccine SWOT Analysis
11.3.6 Merck & Co., Inc. Recent Developments
11.4 Sanofi Pasteur
11.4.1 Sanofi Pasteur Company Information
11.4.2 Sanofi Pasteur Overview
11.4.3 Sanofi Pasteur Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Sanofi Pasteur Pneumonia Vaccine Products and Services
11.4.5 Sanofi Pasteur Pneumonia Vaccine SWOT Analysis
11.4.6 Sanofi Pasteur Recent Developments
11.5 Serum Institute of India Pvt. Ltd.
11.5.1 Serum Institute of India Pvt. Ltd. Company Information
11.5.2 Serum Institute of India Pvt. Ltd. Overview
11.5.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Products and Services
11.5.5 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine SWOT Analysis
11.5.6 Serum Institute of India Pvt. Ltd. Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Information
11.6.2 Johnson & Johnson Overview
11.6.3 Johnson & Johnson Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Johnson & Johnson Pneumonia Vaccine Products and Services
11.6.5 Johnson & Johnson Pneumonia Vaccine SWOT Analysis
11.6.6 Johnson & Johnson Recent Developments
11.7 Astellas Pharma Inc.
11.7.1 Astellas Pharma Inc. Company Information
11.7.2 Astellas Pharma Inc. Overview
11.7.3 Astellas Pharma Inc. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Astellas Pharma Inc. Pneumonia Vaccine Products and Services
11.7.5 Astellas Pharma Inc. Pneumonia Vaccine SWOT Analysis
11.7.6 Astellas Pharma Inc. Recent Developments
11.8 Astrazeneca Plc.
11.8.1 Astrazeneca Plc. Company Information
11.8.2 Astrazeneca Plc. Overview
11.8.3 Astrazeneca Plc. Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Astrazeneca Plc. Pneumonia Vaccine Products and Services
11.8.5 Astrazeneca Plc. Pneumonia Vaccine SWOT Analysis
11.8.6 Astrazeneca Plc. Recent Developments
11.9 CSL Limited
11.9.1 CSL Limited Company Information
11.9.2 CSL Limited Overview
11.9.3 CSL Limited Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 CSL Limited Pneumonia Vaccine Products and Services
11.9.5 CSL Limited Pneumonia Vaccine SWOT Analysis
11.9.6 CSL Limited Recent Developments
11.10 Emergent Biosolutions
11.10.1 Emergent Biosolutions Company Information
11.10.2 Emergent Biosolutions Overview
11.10.3 Emergent Biosolutions Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Emergent Biosolutions Pneumonia Vaccine Products and Services
11.10.5 Emergent Biosolutions Pneumonia Vaccine SWOT Analysis
11.10.6 Emergent Biosolutions Recent Developments
11.11 Walvax Biotechnology
11.11.1 Walvax Biotechnology Company Information
11.11.2 Walvax Biotechnology Overview
11.11.3 Walvax Biotechnology Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Walvax Biotechnology Pneumonia Vaccine Products and Services
11.11.5 Walvax Biotechnology Recent Developments
11.12 Royal (Wuxi) Bio-Pharmaceutical
11.12.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
11.12.2 Royal (Wuxi) Bio-Pharmaceutical Overview
11.12.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Products and Services
11.12.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
11.13 Zhifei Biologic
11.13.1 Zhifei Biologic Company Information
11.13.2 Zhifei Biologic Overview
11.13.3 Zhifei Biologic Pneumonia Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Zhifei Biologic Pneumonia Vaccine Products and Services
11.13.5 Zhifei Biologic Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pneumonia Vaccine Value Chain Analysis
12.2 Pneumonia Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pneumonia Vaccine Production Mode & Process
12.4 Pneumonia Vaccine Sales and Marketing
12.4.1 Pneumonia Vaccine Sales Channels
12.4.2 Pneumonia Vaccine Distributors
12.5 Pneumonia Vaccine Customers
13 Market Dynamics
13.1 Pneumonia Vaccine Industry Trends
13.2 Pneumonia Vaccine Market Drivers
13.3 Pneumonia Vaccine Market Challenges
13.4 Pneumonia Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pneumonia Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Pneumococcal Conjugate Vaccine (PCV13)
Table 3. Major Manufacturers of Pneumococcal Polysaccharide Vaccine (PPSV23)
Table 4. Major Manufacturers of Other
Table 5. Global Pneumonia Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Pneumonia Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Pneumonia Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Pneumonia Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Pneumonia Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Pneumonia Vaccine Revenue Market Share by Region (2024-2034)
Table 11. Global Pneumonia Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 12. Global Pneumonia Vaccine Sales by Region (2018-2024) & (K Doses)
Table 13. Global Pneumonia Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Pneumonia Vaccine Sales by Region (2024-2034) & (K Doses)
Table 15. Global Pneumonia Vaccine Sales Market Share by Region (2024-2034)
Table 16. Global Pneumonia Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 17. Global Pneumonia Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Pneumonia Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Pneumonia Vaccine Revenue Share by Manufacturers (2018-2024)
Table 20. Global Pneumonia Vaccine Price by Manufacturers 2018-2024 (USD/Dose)
Table 21. Global Key Players of Pneumonia Vaccine, Industry Ranking, 2021 VS 2022
Table 22. Global Pneumonia Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Pneumonia Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pneumonia Vaccine as of 2022)
Table 24. Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Pneumonia Vaccine, Product Offered and Application
Table 26. Global Key Manufacturers of Pneumonia Vaccine, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 29. Global Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global Pneumonia Vaccine Sales Quantity Share by Type (2018-2024)
Table 31. Global Pneumonia Vaccine Sales Quantity Share by Type (2024-2034)
Table 32. Global Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Pneumonia Vaccine Revenue Share by Type (2018-2024)
Table 35. Global Pneumonia Vaccine Revenue Share by Type (2024-2034)
Table 36. Pneumonia Vaccine Price by Type (2018-2024) & (USD/Dose)
Table 37. Global Pneumonia Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 39. Global Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global Pneumonia Vaccine Sales Quantity Share by Application (2018-2024)
Table 41. Global Pneumonia Vaccine Sales Quantity Share by Application (2024-2034)
Table 42. Global Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Pneumonia Vaccine Revenue Share by Application (2018-2024)
Table 45. Global Pneumonia Vaccine Revenue Share by Application (2024-2034)
Table 46. Pneumonia Vaccine Price by Application (2018-2024) & (USD/Dose)
Table 47. Global Pneumonia Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America Pneumonia Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Pneumonia Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 50. North America Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 51. North America Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 55. North America Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Pneumonia Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Pneumonia Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 62. North America Pneumonia Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe Pneumonia Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 64. Europe Pneumonia Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 66. Europe Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 70. Europe Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Pneumonia Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Pneumonia Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 77. Europe Pneumonia Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China Pneumonia Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 79. China Pneumonia Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 81. China Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 85. China Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Pneumonia Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 89. APAC Pneumonia Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 91. APAC Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 95. APAC Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Pneumonia Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Pneumonia Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Pneumonia Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Pneumonia Vaccine Sales Quantity by Region (2018-2024) & (K Doses)
Table 102. APAC Pneumonia Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 104. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 110. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 117. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. Pfizer Inc. Company Information
Table 119. Pfizer Inc. Description and Overview
Table 120. Pfizer Inc. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 121. Pfizer Inc. Pneumonia Vaccine Product and Services
Table 122. Pfizer Inc. Pneumonia Vaccine SWOT Analysis
Table 123. Pfizer Inc. Recent Developments
Table 124. Glaxosmithkline Plc. Company Information
Table 125. Glaxosmithkline Plc. Description and Overview
Table 126. Glaxosmithkline Plc. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 127. Glaxosmithkline Plc. Pneumonia Vaccine Product and Services
Table 128. Glaxosmithkline Plc. Pneumonia Vaccine SWOT Analysis
Table 129. Glaxosmithkline Plc. Recent Developments
Table 130. Merck & Co., Inc. Company Information
Table 131. Merck & Co., Inc. Description and Overview
Table 132. Merck & Co., Inc. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 133. Merck & Co., Inc. Pneumonia Vaccine Product and Services
Table 134. Merck & Co., Inc. Pneumonia Vaccine SWOT Analysis
Table 135. Merck & Co., Inc. Recent Developments
Table 136. Sanofi Pasteur Company Information
Table 137. Sanofi Pasteur Description and Overview
Table 138. Sanofi Pasteur Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 139. Sanofi Pasteur Pneumonia Vaccine Product and Services
Table 140. Sanofi Pasteur Pneumonia Vaccine SWOT Analysis
Table 141. Sanofi Pasteur Recent Developments
Table 142. Serum Institute of India Pvt. Ltd. Company Information
Table 143. Serum Institute of India Pvt. Ltd. Description and Overview
Table 144. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 145. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product and Services
Table 146. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine SWOT Analysis
Table 147. Serum Institute of India Pvt. Ltd. Recent Developments
Table 148. Johnson & Johnson Company Information
Table 149. Johnson & Johnson Description and Overview
Table 150. Johnson & Johnson Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 151. Johnson & Johnson Pneumonia Vaccine Product and Services
Table 152. Johnson & Johnson Pneumonia Vaccine SWOT Analysis
Table 153. Johnson & Johnson Recent Developments
Table 154. Astellas Pharma Inc. Company Information
Table 155. Astellas Pharma Inc. Description and Overview
Table 156. Astellas Pharma Inc. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 157. Astellas Pharma Inc. Pneumonia Vaccine Product and Services
Table 158. Astellas Pharma Inc. Pneumonia Vaccine SWOT Analysis
Table 159. Astellas Pharma Inc. Recent Developments
Table 160. Astrazeneca Plc. Company Information
Table 161. Astrazeneca Plc. Description and Overview
Table 162. Astrazeneca Plc. Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 163. Astrazeneca Plc. Pneumonia Vaccine Product and Services
Table 164. Astrazeneca Plc. Pneumonia Vaccine SWOT Analysis
Table 165. Astrazeneca Plc. Recent Developments
Table 166. CSL Limited Company Information
Table 167. CSL Limited Description and Overview
Table 168. CSL Limited Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 169. CSL Limited Pneumonia Vaccine Product and Services
Table 170. CSL Limited Pneumonia Vaccine SWOT Analysis
Table 171. CSL Limited Recent Developments
Table 172. Emergent Biosolutions Company Information
Table 173. Emergent Biosolutions Description and Overview
Table 174. Emergent Biosolutions Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 175. Emergent Biosolutions Pneumonia Vaccine Product and Services
Table 176. Emergent Biosolutions Pneumonia Vaccine SWOT Analysis
Table 177. Emergent Biosolutions Recent Developments
Table 178. Walvax Biotechnology Company Information
Table 179. Walvax Biotechnology Description and Overview
Table 180. Walvax Biotechnology Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 181. Walvax Biotechnology Pneumonia Vaccine Product and Services
Table 182. Walvax Biotechnology Recent Developments
Table 183. Royal (Wuxi) Bio-Pharmaceutical Company Information
Table 184. Royal (Wuxi) Bio-Pharmaceutical Description and Overview
Table 185. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 186. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product and Services
Table 187. Royal (Wuxi) Bio-Pharmaceutical Recent Developments
Table 188. Zhifei Biologic Company Information
Table 189. Zhifei Biologic Description and Overview
Table 190. Zhifei Biologic Pneumonia Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 191. Zhifei Biologic Pneumonia Vaccine Product and Services
Table 192. Zhifei Biologic Recent Developments
Table 193. Key Raw Materials Lists
Table 194. Raw Materials Key Suppliers Lists
Table 195. Pneumonia Vaccine Distributors List
Table 196. Pneumonia Vaccine Customers List
Table 197. Pneumonia Vaccine Market Trends
Table 198. Pneumonia Vaccine Market Drivers
Table 199. Pneumonia Vaccine Market Challenges
Table 200. Pneumonia Vaccine Market Restraints
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources
List of Figures
Figure 1. Pneumonia Vaccine Product Picture
Figure 2. Global Pneumonia Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pneumonia Vaccine Market Share by Type in 2022 & 2034
Figure 4. Pneumococcal Conjugate Vaccine (PCV13) Product Picture
Figure 5. Pneumococcal Polysaccharide Vaccine (PPSV23) Product Picture
Figure 6. Other Product Picture
Figure 7. Global Pneumonia Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Pneumonia Vaccine Market Share by Application in 2022 & 2034
Figure 9. Pneumonia
Figure 10. Meningitis
Figure 11. Sepsis
Figure 12. Pneumonia Vaccine Report Years Considered
Figure 13. Global Pneumonia Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 14. Global Pneumonia Vaccine Revenue 2018-2034 (US$ Million)
Figure 15. Global Pneumonia Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 16. Global Pneumonia Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 17. Global Pneumonia Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 18. Global Pneumonia Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Pneumonia Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 20. North America Pneumonia Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Pneumonia Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 22. Europe Pneumonia Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Pneumonia Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 24. China Pneumonia Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Pneumonia Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 26. APAC Pneumonia Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 28. Middle East, Africa and Latin America Pneumonia Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Pneumonia Vaccine Sales Quantity in 2022
Figure 30. The Top 10 and Top 5 Players Market Share by Pneumonia Vaccine Revenue in 2022
Figure 31. Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 34. Global Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 36. North America Pneumonia Vaccine Revenue Market Share by Company in 2022
Figure 37. North America Pneumonia Vaccine Sales Quantity Market Share by Company in 2022
Figure 38. North America Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 40. North America Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 42. North America Pneumonia Vaccine Revenue Share by Country (2018-2034)
Figure 43. North America Pneumonia Vaccine Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Pneumonia Vaccine Sales Quantity Market Share by Company in 2022
Figure 47. Europe Pneumonia Vaccine Revenue Market Share by Company in 2022
Figure 48. Europe Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 50. Europe Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 52. Europe Pneumonia Vaccine Revenue Share by Country (2018-2034)
Figure 53. Europe Pneumonia Vaccine Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. France Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 59. China Pneumonia Vaccine Sales Quantity Market Share by Company in 2022
Figure 60. China Pneumonia Vaccine Revenue Market Share by Company in 2022
Figure 61. China Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 63. China Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 65. APAC Pneumonia Vaccine Sales Quantity Market Share by Company in 2022
Figure 66. APAC Pneumonia Vaccine Revenue Market Share by Company in 2022
Figure 67. APAC Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 69. APAC Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 71. APAC Pneumonia Vaccine Revenue Share by Region (2018-2034)
Figure 72. APAC Pneumonia Vaccine Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. India Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Pneumonia Vaccine Revenue Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Pneumonia Vaccine Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Pneumonia Vaccine Revenue Share by Country (2018-2034)
Figure 86. Brazil Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Pneumonia Vaccine Revenue (2018-2034) & (US$ Million)
Figure 91. Pneumonia Vaccine Value Chain
Figure 92. Pneumonia Vaccine Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed